NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research”

This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of Solicitation for offers. In accordance with FAR 15.201(d), this Special Notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR).

The FNLCR is a Government-Owned Contractor-Operated Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, Government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute (NCI) under Prime Contract No. 75N91019D00024 & HHSN261201500003I, which provides Operations and Technical Support (OTS) for the FNLCR.

The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this Special Notice as no information is being requested. Please be advised that any submissions provided, despite that no information is requested, become Government property and will not be returned, nor will there be any ensuing discussions or debriefings.

Responses submitted to this Special Notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any.

Description of Work:  In response to the 2018 Ebola outbreak in the Democratic Republic of the Congo (DRC), the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) and Leidos Biomed Research, Inc. (Leidos Biomed) established a multilateral clinical research program called Pamoja Tulinde Maisha (PALM), meaning “Together Save Lives” in the Kiswahili language. This program was founded in partnership with the DRC’s National Institute of Biomedical Research (“Institut National de Recherche Biomédicale” in French). The components of the PALM research program include:

Research Platform: Subcontractor shall provide the core clinical infrastructure and services needed to conduct human subjects’ research. Leidos Biomed has supported NIAID to initiate and sustain clinical research infrastructure across several research sites, laboratories, biorepository, pharmacy cold chain, data management operations, supply chain depots, and administrative/operations offices.

Biorepository: Subcontractor shall provide support for the processing, tracking, storage, and transfer of biospecimens collected during PALM clinical research as well as storage and tracking of outbreak samples.

Subcontractor shall provide support for clinical research protocols:

1. 1. PALM 004, an immunologic sub-study titled “Characterizing the immune responses to Bundibugyo virus disease and their associations with clinical outcomes” at four treatment centers in the outbreak region of Eastern DRC and one research site for recruitment of healthy volunteers in Kinshasa, DRC
   2. PALM 011, an observational cohort study of patients treated for mpox virus disease at two rural hospital sites in the DRC      

Leidos Biomedical Research, Inc. Point of Contact:

If you are interested in obtaining the solicitation, please contact Heather Sewell, Lead Subcontracts Administrator at heather.sewell@nih.gov by 5:00 PM ET Friday, November 20, 2026.